ExpreS2ion announces exercise of 2017 warrant program

Hørsholm, Denmark, August 3, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or “the Company”) today announces that all warrants held by employees and Board members under the 2017 Warrant Program, established in April 2017, have been fully exercised. In total, 436,200 warrants were exercised, providing ExpreS2ion SEK 2,656,632. The exercise has increased the number of shares…

ExpreS2ion’s joint venture AdaptVac signs Final License Agreement with Bavarian Nordic on COVID-19 Vaccine

This is a regulatory release

Hørsholm, Denmark, July 22, 2020 – ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) hereby announces that its joint venture AdaptVac has entered into a final license agreement with Bavarian Nordic A/S (“Bavarian Nordic”), to license the proprietary capsid virus like particle (cVLP) based SARS-CoV-2 subunit vaccine. Under the terms of the agreement, Bavarian Nordic will make an…

Strong Proof-of-Concept for cross-strain protective flu cVLP vaccine further strengthens confidence in Coronavirus vaccine

Hørsholm, Denmark, July 17, 2020 – ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that AdaptVac has announced publication of a paper in the journal Vaccines, where its broadly protective Flu cVLP vaccine induced a more potent, long-lasting immune response and was able to protect mice against both homologous and heterologous H1N1 influenza challenge, even after a single…

ExpreS2ion’s platform to be used in a novel Zika vaccine candidate

Hørsholm, Denmark, July 14, 2020 – ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its ExpreS2[ ]platform will be used in the production of the novel Zika-HX vaccine candidate that is being developed by Excivion Ltd., a UK-based biotechnology company. The manufacturing of the Zika-HX vaccine will be conducted together with CPI, a British independent technology innovation…

ExpreS2ion provides update on negotiations with Bavarian Nordic and progress towards clinical Phase I/IIa trial

This is a regulatory release

Hørsholm, Denmark, July 08, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the cVLP COVID-19 vaccine license agreement negotiation between its joint venture AdaptVac and Bavarian Nordic is expected to continue beyond the previously announced two months’ time frame. The timeline of the already fully funded Phase I/IIa trial is not affected. Process…

ExpreS2ion announces that the cVLP COVID-19 vaccine shows strong virus neutralization properties in animal proof-of-concept data

This is a regulatory release

Hørsholm, Denmark, June 09, 2020 – ExpreS[2]ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the capsid virus-like particle (cVLP) COVID-19 vaccine being developed by ExpreS2ion and its joint venture AdaptVac has demonstrated excellent COVID-19 immunization with very high level of SARS-CoV-2 virus neutralization in a mice model, thus reaching an important pre-clinical milestone ahead of…

Communique from the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is a regulatory release

Today, on May 26[th], 2020, the Annual General Meeting (“AGM”) was held in ExpreS2ion Biotech Holding AB (“ExpreS2ion”). Below follows a summary of the resolutions. The resolutions were passed with the required majority.

ExpreS2ion – Interim report for the first quarter 2020 published

This is a regulatory release

Hørsholm, Denmark, May 20, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's interim report for the first quarter 2020 is published. The interim report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion Announces Bavarian Nordic Enters Agreement with AdaptVac to Advance the COVID-19 Vaccine Program

This is a regulatory release

Hørsholm, Denmark, May 06, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that its joint venture AdaptVac has entered into an exclusive head of terms agreement with Bavarian Nordic, a global leader in the development, manufacture and commercialization of life-saving vaccines, to license the COVID-19 vaccine. The parties seek to enter into the final…

ExpreS2ion - Annual report for 2019 published

This is a regulatory release

Hørsholm, Denmark, May 05, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's annual report for the financial year 2019 is published. The annual report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com).

ExpreS2ion announces last part of loan conversion and new loan facility

This is a regulatory release

Hørsholm, Denmark, May 04, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that SEK 1.75 million (excluding accrued interest) of the loan provided by Modelio Equity AB (https://news.cision.com/expres2ion-biotechnologies/r/expres-2-ion-secures-sek-8-million-in-bridge-financing-to-facilitate-further-growth,c2933530) (“Modelio”) will be converted into new shares at a price of approximately SEK 9.06 (corresponding to a 10% discount off the last 15 trading days volume-weighted average…

ExpreS2ion announces supporting an advantageous COVID-19 diagnostic antibody development project

Hørsholm, Denmark, May 4, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that its SARS-CoV-2 antigen is being applied across multiple research and development projects, including an on-going diagnostic antibody test program that Rigshospitalet, University of Copenhagen and Novo Nordisk jointly develop to support the diagnosis…

ExpreS2ion announces selection of AGC Biologics as manufacturing partner for the COVID-19 vaccine and provides update to the program

This is a regulatory release

Hørsholm, Denmark, April 24, 2020 – Today, ExpreS[2]ion Biotechnologies ApS (“ExpreS[2]ion”), a fully owned subsidiary of ExpreS[2]ion Biotech Holding AB, announces that its joint venture AdaptVac and AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals enters into a partnership for the scale-up and cGMP manufacture of the COVID-19 vaccine developed by…

Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is a regulatory release

The shareholders of ExpreS2ion Biotech Holding AB (publ), 559033-3729, are hereby invited to attend the Annual General Meeting on Tuesday, May 26, 2020, at 4:00 p.m. at Clarion Grand Hotel, Stortorget 8, in Helsingborg.

ExpreS2ion announces loan conversion

This is a regulatory release

Hørsholm, Denmark, April 21, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that SEK 1.75 million (excluding accrued interest) of the loan provided by Modelio Equity AB (https://news.cision.com/expres2ion-biotechnologies/r/expres-2-ion-secures-sek-8-million-in-bridge-financing-to-facilitate-further-growth,c2933530) will be converted into new shares at a price of SEK 6.4925 (corresponding to the last 15 trading days volume-weighted average share price).

ExpreS2ion’s CSO Dr. Wian de Jongh co-signs WHO-sanctioned statement from 83 COVID-19 vaccine researchers

Hørsholm, Denmark, April 15, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the company’s Chief Scientific Officer Dr. Wian de Jongh is a co-signer of a WHO statement from 83 COVID-19 vaccine researchers from all over the world. The statement encourages everyone to follow recommendations…

ExpreS2ion announces 6.7 MSEK EU Horizon 2020 grant for the development of a unique influenza vaccine

This is a regulatory release

Hørsholm, Denmark, March 31, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the international next-generation influenza vaccine consortium INDIGO, led by the University of Amsterdam with ExpreS2ion as a participating member, has been awarded a 10.0 MEUR Horizon 2020 grant from the EU. ExpreS2ion’s participation…

ExpreS2ion rearranges its event schedule due to Coronavirus restrictions

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is rearranging its recently communicated event schedule due to events changes as a results of COVID-19-related travel restrictions. The company’s main priority during this time is to progress rapidly with the ongoing EU Horizon 2020-funded COVID-19 vaccine development project together with the rest of the consortium…

ExpreS2ion announces EU grant award for the COVID-19 vaccine development programme

This is a regulatory release

Hørsholm, Denmark, March 6, 2020 – Today, ExpreS[2]ion Biotechnologies ApS (“ExpreS[2]ion”), a fully owned subsidiary of ExpreS[2]ion Biotech Holding AB, announces that the consortium has been awarded an EU Horizon 2020 grant for the COVID-19 (SARS-CoV-2) Coronavirus vaccine development programme. The award funding amounts to 2,7 MEUR (28MSEK), of which ExpreS[2]ion directly is funded with…

ExpreS2ion will present its ExpreS2 platform and pipeline at several key events in March and April 2020

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate at several key events in March and April, including Aktiespararna’s Aktiedagen, March 16 in Stockholm, Sweden, BIO-Europe Spring, March 23-25 in Paris, France, and World Vaccine Congress, April 6-8 in Washington, DC, USA.

ExpreS2ion Biotech Holding AB: Publication of Year-End Report 2019

This is a regulatory release

Hørsholm, Denmark, February 26, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes its Year-End Report for the period January – December 2019. The report is available as an attached document to this press release and on the company’s website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion will be allocated approximately SEK 9,6 million through the redemption of warrants and at the same time converts part of loan

This is a regulatory release

Hørsholm, Denmark, February 26, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company has received written confirmation from warrant holders that these parties will exercise all of their warrants of series TO 3. ExpreS2ion will thereby be allocated approximately SEK 9.6 million before issue costs. In connection with this share issue SEK…

ExpreS2ions Year-End Report for 2019 will be published today

This is a regulatory release

Hørsholm, Denmark, February 26, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company’s Year-End Report for 2019 will be published today, as the report is finalized earlier than planned. Previous date for publication of the report was on Friday, the 28[th] of February, 2020.

ExpreS2ion Signs Option to License Agreement with AdaptVac Regarding Unique Breast Cancer Vaccine

This is a regulatory release

Hørsholm, Denmark, February 26, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the company has signed an Option to License Agreement (“Agreement”) with AdaptVac ApS (“AdaptVac”) whereby ExpreS2ion may call an option to exclusively license in AV001 (HER2-cVLP), a preclinical-stage novel breast cancer vaccine candidate,…

ExpreS2ion’s joint venture AdaptVac receives Eurostars grant to further support its HER2 vaccine project AV001

This is a regulatory release

Hørsholm, Denmark, February 25, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that a consortium led by the company’s joint venture AdaptVac has been awarded a 0.6 MEUR Eurostars grant, of which AdaptVac directly receives 1.3 MDKK (1.8 MSEK). The grant will support pre-clinical safety and…

ExpreS2ion to lead European COVID-19 vaccine consortium for rapid clinical development

This is a regulatory release

Hørsholm, Denmark, February 24, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the company will lead a consortium of European expert entities in applying for the EU Horizon 2020 and the Coalition for Epidemic Preparedness Innovations (CEPI) grant calls for COVID-19 (SARS-CoV-2) Coronavirus vaccine development.…

ExpreS2ion announces initiation of a Wuhan Coronavirus vaccine program

This is a regulatory release

Hørsholm, Denmark, February 6, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces the initiation of a Wuhan Coronavirus (2019-nCoV) vaccine program. ExpreS2ion will produce viral antigens needed for diagnostics and vaccine research, focused on internal vaccine development efforts. The program’s first stage has a timeline of…

ExpreS2ion’s CEO in interview on 2019 and the company’s new way forward with a stronger pipeline focus

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) publishes an interview with newly appointed CEO Bent Frandsen upon shareholder request. The company’s new way forward with Bent at the helm will include a much stronger focus on building a pipeline portfolio with assets developed in the ExpreS2 platform.

ExpreS2ion is streamlining its market communication with English as primary language

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the company has chosen to streamline its market communication, and will only provide press releases and interim reports in English. ExpreS2ion’s annual report will continue to be published in both Swedish and English. 

ExpreS2ion’s joint venture AdaptVac granted US patent for its core platform technology

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture company AdaptVac ApS (“AdaptVac”) has been granted a US patent covering its core technology platform. This confirms the overall patentability and proprietary protection of AdaptVac’s entire pipeline and future projects. In particular, this consolidates the position of the AV001 breast cancer vaccine for which a…

ExpreS2ion appoints Bent U. Frandsen as Chief Executive Officer

This is a regulatory release

ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) today announces that the Company’s Board of Directors has appointed Bent U. Frandsen as the new Chief Executive Officer of ExpreS[2]ion, succeeding Steen Klysner as of today 20 December, 2019. Bent has been with ExpreS[2]ion since March 2016 and has served as the Company’s Chief Business Officer since August 2018.

ExpreS2ion has been awarded SEK 2.7 million for continued development of two malaria vaccine candidates

This is a regulatory release

ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) announces that the Company has been awarded SEK 2.7 million as part of the Horizon 2020-funded OptiMalVax grant consortium, led by Jenner Institute at the University of Oxford, to establish monoclonal Drosophila S2 cell banks for two new malaria vaccine candidates. One targets blood-stage malaria, potentially in combination with the…

ExpreS2ion Biotech Holding AB: Publication of interim report for January – September 2019

This is a regulatory release

ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) hereby publishes its interim report for the period January – September 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.

Breakthrough: ExpreS2ion launches first unique cell line for enhanced efficacy of vaccines and immunotherapy

This is a regulatory release

After several years of research and development, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces the launch of a new tailormade S2 cell line, HighMan-S2™. This is the first member of ExpreS2ion’s new functionally modified S2 product line, GlycoX-S2™, which utilises and expands the advantages of the ExpreS2 platform.

ExpreS2ion’s joint venture AdaptVac receives Danish InnoBooster grant of 1.2 MSEK for for breast cancer studies in dogs

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces today that its joint venture company AdaptVac ApS (“AdaptVac”) has been awarded an InnoBooster grant by the Danish Innovation Foundation worth 0.8 MDKK (approx. 1.2 MSEK). The grant provides further resources for the development of a safe and effective treatment for dogs diagnosed with DER2+ cancer. In addition to…

ExpreS 2 ion secures SEK 8 million in bridge financing to facilitate further growth

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the Company is increasing its working capital by securing a combination of a bridge loan and a loan facility of up to SEK 8 million in total. This will enable ExpreS2ion to further expand its business activities in line with the growth numbers reported for Q1 and Q2…

New date for publication of interim report 3

This is a regulatory release

Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the Company will publish its interim report for the period January – September 2019 on November 14th, 2019, instead of the previously scheduled November 21st, 2019. The aim of the advanced publication is to coordinate the release with the Company’s planned participation in a major public investor…

ExpreS2ion receives 1.6 MSEK order in development program for next-generation malaria vaccine

This is a regulatory release

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that it has received a 1.6 MSEK order to perform development work as part of a Wellcome Trust funded malaria vaccine project. The project is led by Jenner Institute at the University of Oxford, and the goal is to create a…

ExpreS 2 ion Biotech Holding AB: Publication of interim report for January – June 2019

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes its interim report for the period January – June 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion’s licensee Institut Virion\Serion launches the first in vitro diagnostic product based on the ExpreS2-platform

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the Company’s entry on the market for in vitro diagnostic (IVD) applications through its Germany-based licensee Institut Virion\Serion GmbH (“Virion”). Virion is now launching a unique Zika NS1 viral antigen produced in the ExpreS2 platform, and over the next 18 months Virion will increase its offering of products using…

ExpreS2ion licenses groundbreaking CRISPR/Cas9 gene editing technology from ERS Genomics

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the signing of a non-exclusive license agreement with ERS Genomics, providing ExpreS2ion with the right to use and commercialise products, for its own use or together with customers or partners, based on the highly efficient CRISPR/Cas9 gene editing technology. This will enable the Company to offer a whole new…

Change of Certified Adviser to Svensk Kapitalmarknadsgranskning AB

This is a regulatory release

ExpreS2ion Biotech Holding AB (publ) has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (“SKMG”) regarding Certified Adviser services. SKMG will be appointed as Certified Adviser on the 1st of July 2019. Until the 1st of July 2019, Sedermera Fondkommission will continue to act as Certified Adviser for the Company.

ExpreS2ion co-author of article demonstrating that human antibodies from RH5 vaccine block binding to blood cells

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that a scientific article, documenting that human antibodies against the RH5 protein can stop the malaria parasite from entering human blood cells, has been published in the highly renowned journal Cell. The article is based on a clinical study conducted by researchers at the University of Oxford together with…

Report from ExpreS2ion Biotech Holding AB’s (publ) annual general meeting

This is a regulatory release

This is an unofficial translation of a report from the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. Today, on May 23, 2019, the annual general meeting of ExpreS2ion Biotech Holding AB (publ) was…

ExpreS2ion Biotech Holding AB: Publication of interim financial report for January – March 2019

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes financial report for the period of January – March 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion Biotech Holding AB: Publication of Annual Report for the fiscal year 2018

This is a regulatory release

The Board of Directors and the Chief Executive Officer of ExpreS2ion Biotech Holding AB hereby publishes the Annual Report for the fiscal year 2018. The Annual Report and the accompanying Auditor’s Report is available on the Company’s website (www.expres2ionbio.com).

ExpreS2ion announces the publication of a proof of concept in animals for a new potential breakthrough malaria vaccine

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the publication of a scientific article in Cellular Microbiology providing the first proof of concept in an animal model for a next generation malaria vaccine that is targeting a recently discovered molecular ’key’ that the deadly malaria parasite uses to enter human blood cells.

Correction: Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is a regulatory release

This is an unofficial translation of a notice to the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), 559033-3729, are hereby invited to attend the Annual…

Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is a regulatory release

This is an unofficial translation of a notice to the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), 559033-3729, are hereby invited to attend the Annual…

ExpreS2ion Biotechnologies Announces Research License Agreement with Mitsubishi Tanabe Pharma Corporation

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, has signed a two-year Research License Agreement granting Mitsubishi Tanabe Pharma Corporation access to use ExpreS2ion’s proprietary protein expression platform, ExpreS2 TM , in their Research and Development (R&D).